Attached files

file filename
EX-99.1 - EX-99.1 - Microbot Medical Inc.exhibit1.htm
 

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   March 24, 2015

StemCells, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-19871 94-3078125
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
7707 Gateway Blvd, Suite 140, Newark, California   94560
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   510.456.4000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 24, 2015, StemCells, Inc. (the "Company") announced the appointment of Ian Massey, D. Phil., as its President and Chief Operating Officer reporting to Mr. Martin McGlynn, effective March 23, 2015. Mr. McGlynn continues to serve as the Company’s Chief Executive Officer and on its Board of Directors, while Dr. Massey succeeds him as President. In his new role, Dr. Massey will be responsible for all aspects of the Company’s research and development, manufacturing, regulatory affairs, and quality assurance activities.

A copy of the press release announcing the appointment of Dr. Massey is attached hereto as Exhibit 99.1.





Item 9.01 Financial Statements and Exhibits.

Exhibit 99.1 Press Release, dated March 24, 2015, announcing the appointment of Dr. Ian Massey to the Company’s executive team as President and Chief Operating Officer.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    StemCells, Inc.
          
March 24, 2015   By:   Kenneth Stratton
       
        Name: Kenneth Stratton
        Title: General Counsel


Exhibit Index


     
Exhibit No.   Description

 
99.1
  Press release dated March 24, 2015